HARBIN PHARMACEUTICAL GROUP; HOLDING CO., LTD

HAYAO

Medicines for human purposes; cachets for pharmaceutical purposes; injection (terms considered too vague by the International Bureau - Rule 13(2)(b) of the Common Regulations under the Madrid Agreement and Protocol); tablet (terms considered too vague by the International Bureau - Rule 13(2)(b) of the Common Regulations under the Madrid Agreement and Protocol); API (Active Pharmaceutical Ingredient) (terms considered too vague by the International Bureau - Rule 13(2)(b) of the Common Regulations under the Madrid Agreement and Protocol); pulvis, (terms considered too vague by the International Bureau - Rule 13(2)(b) of the Common Regulations under the Madrid Agreement and Protocol) pharmaceutical preparations; pharmaceutical preparations; chemico-pharmaceutical preparations;Color is not claimed as a feature of the mark.;The English translation of the foreign word(s) in the mark is: HARBIN PHARMACEUTICAL GROUP.;

HPGC

Nutritional capsules, not for medical purpose, nutritional powder, not for medical purpose, nutrient fluid, not for medical purpose, nutritional ointment, not for medical purpose (all aforementioned terms considered too vague by the International Bureau - Rule 13(2)(b) of the Common Regulations under the Madrid Agreement and Protocol); royal jelly for human consumption (not for medical purposes);Pharmaceutical preparations; chemico-pharmaceutical preparations; cachets for pharmaceutical purposes; injection (terms considered too vague by the International Bureau - Rule 13(2)(b) of the Common Regulations under the Madrid Agreement and Protocol); Chinese patent drugs; medicines for human purposes; tablet (terms considered too vague by the International Bureau - Rule 13(2)(b) of the Common Regulations under the Madrid Agreement and Protocol); medicinal extracts; water aqua (terms considered too vague by the International Bureau - Rule 13(2)(b) of the Common Regulations under the Madrid Agreement and Protocol); API (active pharmaceutical ingredient) (terms considered too vague by the International Bureau - Rule 13(2)(b) of the Common Regulations under the Madrid Agreement and Protocol); medical preparations for slimming purposes; medicines for dental purposes; diagnostic preparations for medical purposes; medicinal drinks; amino acids for medical purposes; tinctures; medicinal oils (antirheumatic tinctures); oils (treatment for common cold); menthocamphorate) (terms considered too vague by the International Bureau - Rule 13(2)(b) of the Common Regulations under the Madrid Agreement and Protocol); radiopharmaceuticals; medicated wine (terms considered too vague by the International Bureau - Rule 13(2)(b) of the Common Regulations under the Madrid Agreement and Protocol); blood plasma; pharmaceutical preparations for treating dandruff; dietetic substances adapted for medical use; dietetic food preparations adapted for medical purposes; biochemicals; blood products; gelatin pearl (terms considered too vague by the International Bureau - Rule 13(2)(b) of the Common Regulations under the Madrid Agreement and Protocol); syrups for pharmaceutical purposes; eye-wash; vitamin preparations; vaccines; decoctions for pharmaceutical purposes; disinfectants for hygiene purposes; medicinal infusions; medicinal tea; gelatin for medical purposes; medicinal herbs; lotions for pharmaceutical purposes; liniments; serums; opotherapy preparations; pills for pharmaceutical purposes; pharmaceutical preparations for skin care; tonics (medicine); suppositories; sunburn ointments; royal jelly (for medical purposes);HARBIN PHARMACEUTICAL GROUP;Color is not claimed as a feature of the mark.;The English translation of the foreign word(s) in the mark is: HARBIN PHARMACEUTICAL GROUP.;